Source:http://linkedlifedata.com/resource/pubmed/id/15095405
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2004-4-19
|
pubmed:abstractText |
To further define the role of insulin-like growth factor-1 (IGF-1) and its receptor (IGF-1R) in osteosarcoma (OS), human OS cell lines with low (SAOS-2) and high (SAOS-LM2) metastatic potential and three canine OS-derived cell lines were studied. Cell lines were evaluated for: IGF-1R expression; expression of IGF binding proteins (IGFBPs); effect of IGF-1 on tumor cell growth, invasion, expression of urokinase plasminogen activator (uPA), and soluble uPA receptor (suPAR), and; ectopic and orthotopic tumorigenicity of the canine OS cells in athymic mice. All cell lines exhibited steady-state mRNA expression of IGF-1R. The SAOS-2 and SAOS-LM2 cells expressed 9,138 and 10,234 cell-associated binding sites, respectively. Canine OS cells expressed from 1,728 to 3,883 binding sites. Two IGF-1-treated cell lines displayed enhanced proliferation. Two cell lines formed colonies in semisolid media, and IGF-1 increased colony number. Matrigel invasion was enhanced in one cell line following IGF-1 treatment. uPA and suPAR were unchanged in SAOS-2 and SAOS-LM2 cells following IGF-1 treatment, but the highly metastatic OS line SAOS-LM2 expressed five times more suPAR and displayed enhanced invasion compared to the parental, low metastatic SAOS-2. IGFBP-5 was detected in four of five cell lines, and IGFBP-3 was detected in two canine OS cell lines. Two canine OS lines were tumorigenic, and one metastasized spontaneously. In conclusion, OS cells express IGF-1R, which can contribute to their growth and invasion. There is suggestive evidence that increasing receptor number may contribute to in vivo tumorigenesis. Additional studies are needed to determine how IGF-1/IGF-1R interactions contribute to the malignant phenotype of OS.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0730-2312
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2004 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
77-91
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:15095405-Animals,
pubmed-meshheading:15095405-Bone Neoplasms,
pubmed-meshheading:15095405-Cell Line,
pubmed-meshheading:15095405-Dogs,
pubmed-meshheading:15095405-Gene Expression,
pubmed-meshheading:15095405-Humans,
pubmed-meshheading:15095405-Insulin-Like Growth Factor I,
pubmed-meshheading:15095405-Lung,
pubmed-meshheading:15095405-Mice,
pubmed-meshheading:15095405-Mice, Nude,
pubmed-meshheading:15095405-Neoplasm Transplantation,
pubmed-meshheading:15095405-Osteosarcoma,
pubmed-meshheading:15095405-Protein Binding,
pubmed-meshheading:15095405-Receptor, IGF Type 1,
pubmed-meshheading:15095405-Transplantation, Heterologous,
pubmed-meshheading:15095405-Urokinase-Type Plasminogen Activator
|
pubmed:year |
2004
|
pubmed:articleTitle |
IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.
|
pubmed:affiliation |
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|